<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CPR</journal-id>
<journal-id journal-id-type="hwp">spcpr</journal-id>
<journal-title>European Journal of Preventive Cardiology</journal-title>
<issn pub-type="ppub">2047-4873</issn>
<issn pub-type="epub">2047-4881</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1741826710396625</article-id>
<article-id pub-id-type="publisher-id">10.1177_1741826710396625</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Exercise testing</subject>
<subj-group subj-group-type="heading">
<subject>Original scientific papers</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>A new cardiopulmonary exercise testing prognosticating algorithm for heart failure patients treated with beta-blockers</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Corrà</surname><given-names>Ugo</given-names></name>
<xref ref-type="aff" rid="aff1-1741826710396625">1</xref>
<xref ref-type="corresp" rid="corresp1-1741826710396625"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Mezzani</surname><given-names>Alessandro</given-names></name>
<xref ref-type="aff" rid="aff1-1741826710396625">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Giordano</surname><given-names>Andrea</given-names></name>
<xref ref-type="aff" rid="aff2-1741826710396625">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Caruso</surname><given-names>Roberto</given-names></name>
<xref ref-type="aff" rid="aff1-1741826710396625">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Giannuzzi</surname><given-names>Pantaleo</given-names></name>
<xref ref-type="aff" rid="aff1-1741826710396625">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-1741826710396625"><label>1</label>Division of Cardiology, Salvatore Maugeri Foundation, IRCCS, Veruno, Italy.</aff>
<aff id="aff2-1741826710396625"><label>2</label>Bioengineering Department, Salvatore Maugeri Foundation, IRCCS, Via per Revislate 13, 28010 Veruno, Italy.</aff>
<author-notes>
<corresp id="corresp1-1741826710396625">Ugo Corrà, Divisione di Cardiologia, Laboratory for the Analysis of Cardio-respiratory Signals, IRCCS Fondazione ‘S. Maugeri’. Via per Revislate, 13, 28010 Veruno (NO), Italy Email: <email>ucorra@fsm.it</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2012</year>
</pub-date>
<volume>19</volume>
<issue>2</issue>
<fpage>185</fpage>
<lpage>191</lpage>
<history>
<date date-type="rev-recd"><day>27</day><month>7</month><year>2010</year></date>
<date date-type="accepted"><day>13</day><month>12</month><year>2010</year></date>
</history>
<permissions>
<copyright-statement>© The European Society of Cardiology 2011 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="society">European Society of Cardiology</copyright-holder>
</permissions>
<abstract>
<p>In 2004, a cardiopulmonary exercise testing (CPET) prognosticating algorithm for heart failure (HF) patients was proposed. The algorithm employed a stepwise assessment of peak oxygen consumption (VO2), slope of regression relating minute ventilation to carbon dioxide output (VE/VCO2) and peak respiratory exchange ratio (RER), and was proposed as an alternative to the traditional strategy of using a single CPET parameter to describe prognosis. Since its initial proposal, the prognosticating algorithm has not been reassessed, although a re-evaluation is in order given the fact that new HF therapies, such as beta-blocker therapy, have significantly improved survival in HF. The present review, based on a critical examination of CPET outcome studies in HF patients regularly treated with beta-blockers, suggests a new prognosticating algorithm. The algorithm comprises four CPET parameters: peak RER, exertional oscillatory ventilation (EOV), peak VO2 and peak systolic blood pressure (SBP). Compared to previous proposals, the present preliminary attempt includes EOV instead of VE/VCO2 slope as ventilatory CPET parameter, and peak SBP as hemodynamic-derived index.</p>
</abstract>
<kwd-group>
<kwd>Heart failure</kwd>
<kwd>cardiopulmonary testing</kwd>
<kwd>prognosis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-1741826710396625" sec-type="intro"><title>Introduction</title>
<p>Today, most heart failure (HF) patients referred for functional evaluation are on beta-blocker therapy and, given the effect of beta-blockers on mortality,<sup><xref ref-type="bibr" rid="bibr1-1741826710396625">1</xref>,<xref ref-type="bibr" rid="bibr2-1741826710396625">2</xref></sup> the estimated mortality rate at all levels of severity of HF would be expected to be significantly lower compared to the pre-beta-blocker era. Thus, the implication for the overall prognostic meaning of the cardiopulmonary exercise testing (CPET) prognostic indexes is that they would be, in the least analysis, overestimated in the presence of beta-blocker therapy<sup><xref ref-type="bibr" rid="bibr3-1741826710396625">3</xref></sup> or even perhaps distorted.</p>
<p>The aim of the present review, based on a critical examination of outcome CPET studies in HF patients regularly treated with beta-blockers, was to reappraise the previous proposed CPET prognosticating algorithm<sup><xref ref-type="bibr" rid="bibr4-1741826710396625">4</xref></sup> and recommend an updated algorithm for the individual HF patient on beta-blocker therapy.</p>
</sec>
<sec id="sec2-1741826710396625"><title>Effect of beta-blocker agents on exercise capacity and ventilatory response</title>
<sec id="sec3-1741826710396625"><title>Effect of beta-blocker agents on exercise capacity</title>
<p>Although beta-blockers have been shown to increase left and right ventricular ejection fraction, reverse ventricular remodeling, improve quality of life, reduce hospital admissions and improve survival in HF,<sup><xref ref-type="bibr" rid="bibr1-1741826710396625">1</xref>,<xref ref-type="bibr" rid="bibr2-1741826710396625">2</xref></sup> they have not significantly improved peak VO2.<sup><xref ref-type="bibr" rid="bibr5-1741826710396625">5</xref></sup> Aerobic capacity has shown an improvement only with metoprolol,<sup><xref ref-type="bibr" rid="bibr6-1741826710396625">6</xref></sup> because of its increasing beta1-receptor density and lack of beta2-receptor blockade, whereas the third generation beta-blockers, carvedilol and bucindolol, down-regulate the beta-receptor, block some or all beta2-receptors, and lower systemic and cardiac norepinephrine levels, leading to a gain in cardiac function but associated with a lack of exercise improvement.<sup><xref ref-type="bibr" rid="bibr7-1741826710396625">7</xref></sup> A large component of this limitation may be related to the blunting of peak exercise heart rate, although peripheral circulation adaptations, metabolic effects and skeletal muscle response may also be affected by beta-blocker therapy.<sup><xref ref-type="bibr" rid="bibr8-1741826710396625">8</xref></sup></p>
</sec>
<sec id="sec4-1741826710396625"><title>Effect of beta-blocker agents on ventilatory response</title>
<p>Ventilatory efficiency – typically expressed as the minute ventilation/carbon dioxide production (VE/VCO2) slope – depends on pulmonary haemodynamics and the resulting ventilation-perfusion mismatch, skeletal muscle ergoreceptor and peripheral chemoreceptor sensitivity, and heightened sympathetic activity.<sup><xref ref-type="bibr" rid="bibr9-1741826710396625">9</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr12-1741826710396625">12</xref></sup> VE/VCO2 slope is enhanced in HF and is a strong prognostic marker.<sup><xref ref-type="bibr" rid="bibr10-1741826710396625">10</xref>,<xref ref-type="bibr" rid="bibr12-1741826710396625">12</xref>,<xref ref-type="bibr" rid="bibr13-1741826710396625">13</xref></sup></p>
<p>Exercise-induced hyperventilation in HF is based on an increase (47%) in carbon dioxide production (VCO2), an increase (45%) in the physiological dead space/tidal volume ratio (VD/VT) and a reduction (8%) of partial pressure of CO2 in arterial blood (PaCO2).<sup><xref ref-type="bibr" rid="bibr10-1741826710396625">10</xref></sup> Moreover, HF patients display reduced functional residual capacity at the beginning of exercise, but when they reach an early expiratory flow limitation they increase their functional residual capacity to increase ventilation.<sup><xref ref-type="bibr" rid="bibr11-1741826710396625">11</xref></sup> The increase in functional residual capacity, the reduced expiratory time and the presence of uneven lung compliance produces inhomogeneity of end expiratory alveolar pressure which in turn leads to ventilation/perfusion inhomogeneity.<sup><xref ref-type="bibr" rid="bibr12-1741826710396625">12</xref></sup> The following equation regulates ventilation (VE):
<disp-formula id="disp-formula1-1741826710396625"><graphic xlink:href="10.1177_1741826710396625-eq1.tif"/></disp-formula></p>
<p>In the above equation in steady state conditions, VCO2 depends on muscle work; PaCO2 depends on the chemoreceptor CO2 set-point, which is genetically determined but, in HF, also significantly related to enhanced chemo- and metabo-reflex activity;<sup><xref ref-type="bibr" rid="bibr12-1741826710396625">12</xref></sup> VD/VT is the ratio between dead space (waste) volume and tidal volume. VD/VT depends on ventilation/perfusion matching but also on lung diffusion capability. All these variables are under sympathetic control and therefore a possible target of beta-blockers.<sup><xref ref-type="bibr" rid="bibr11-1741826710396625">11</xref></sup> Several reports on small HF cohorts have shown that long-term beta-blocker therapy reduces VE/VCO2 slope, particularly in HF patients with an elevated value of VE/VCO2 slope before treatment.<sup><xref ref-type="bibr" rid="bibr14-1741826710396625">14</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr18-1741826710396625">18</xref></sup></p>
<p>Irrespective of different definition criteria,<sup><xref ref-type="bibr" rid="bibr19-1741826710396625">19</xref></sup> exertional oscillatory ventilation (EOV) is an ominous ventilatory pattern in HF.<sup><xref ref-type="bibr" rid="bibr20-1741826710396625">20</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr23-1741826710396625">23</xref></sup> The underlying mechanistic theory of EOV takes into account on one hand the ratio of augmented lung to chemoreceptor circulation time, generating a delay negative feedback loop that modulates ventilation and blood gas tension; on the other, the impaired ventilatory control due several factors, including an increased central and/or peripheral chemoreceptor sensitivity, the elevated LV filling pressure and the interstitial pulmonary edema.<sup><xref ref-type="bibr" rid="bibr24-1741826710396625">24</xref></sup> Importantly, HF patients with EOV exhibit a wide range of VE/VCO2 slope values,<sup><xref ref-type="bibr" rid="bibr20-1741826710396625">20</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr23-1741826710396625">23</xref></sup> and, although both EOV and VE/VCO2 slope are acknowledged risk factors, their predictive value is independent. EOV has been claimed to be superior in different HF populations.<sup><xref ref-type="bibr" rid="bibr20-1741826710396625">20</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr22-1741826710396625">22</xref></sup> The prognostic EOV and VE/VCO2 slope discrepancy is not fully elucidated yet, and it may be related to a complex interplay between pathogenetic contributors of enhanced exertional ventilatory response and disease time-course.<sup><xref ref-type="bibr" rid="bibr25-1741826710396625">25</xref>,<xref ref-type="bibr" rid="bibr26-1741826710396625">26</xref></sup> Unfortunately, the effect of beta-blockers on EOV prognostic value has not yet been investigated.</p>
</sec>
</sec>
<sec id="sec5-1741826710396625"><title>Prognostic meaning of CPET parameters in the beta-blocker era</title>
<sec id="sec6-1741826710396625"><title>Prognostic value of peak VO2</title>
<p>Few studies have evaluated the prognostic value of CPET risk parameters in HF patients regularly treated with beta–blockers (<xref ref-type="table" rid="table1-1741826710396625">Tables 1</xref>), but beta–blocker patients generally showed a better 1- and 3-year outcome at comparable peak VO2 in relation to patients not on beta-blocker:<sup><xref ref-type="bibr" rid="bibr27-1741826710396625">27</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr32-1741826710396625">32</xref></sup> beta-blocker use was associated with improved survival in a wide range of peak VO2 – 10–25 ml/kg/min,<sup><xref ref-type="bibr" rid="bibr31-1741826710396625">31</xref></sup> and beta-blocker HF patients have a better prognosis to that of patients who undergo heart transplantation (HT), as long as they have peak VO2 &gt;12 ml/kg/min.<sup><xref ref-type="bibr" rid="bibr29-1741826710396625">29</xref></sup>
<table-wrap id="table1-1741826710396625" position="float"><label>Table 1.</label><caption><p>Demographic, functional characteristics and survival trends in clinical trials with cardiopulmonary exercise testing in heart failure patients regularly treated with beta-blockers</p></caption>
<graphic alternate-form-of="table1-1741826710396625" xlink:href="10.1177_1741826710396625-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Author </th>
<th>Patients <italic>N</italic></th>
<th>Male <italic>N</italic> (%)</th>
<th>Sinus rhythm <italic>N</italic> (%)</th>
<th>Mean peak VO2 (ml/kg/min)</th>
<th>Mean peak RER</th>
<th>Mean follow up (years)</th>
<th>Overall mean survival (%)</th>
<th>Comments</th></tr></thead>
<tbody align="left">
<tr>
<td align="justify">Zugck C<sup><xref ref-type="bibr" rid="bibr27-1741826710396625">27</xref></sup></td>
<td align="justify">165</td>
<td align="justify">140 (85)</td>
<td align="justify">NA</td>
<td align="justify">14.4 ± 5.2</td>
<td align="justify">NA</td>
<td align="justify">1</td>
<td align="justify">94</td>
<td align="justify">Pts with peak VO2≤10 ml/kg/min showed a 83% 1-year survival</td></tr>
<tr>
<td align="justify">Peterson LR<sup><xref ref-type="bibr" rid="bibr28-1741826710396625">28</xref></sup></td>
<td align="justify">199</td>
<td align="justify">114 (57)</td>
<td align="justify">NA</td>
<td align="justify">17 ± 5</td>
<td align="justify">1.14 ± 0.13</td>
<td align="justify">1.6</td>
<td align="justify">NA</td>
<td align="justify">Pts with peak VO2 ≤ 10 ml/kg/min. and those with peak VO2 between 10 and 12 ml/kg/min showed more than 75% mean survival<sup><xref ref-type="table-fn" rid="table-fn2-1741826710396625">a</xref></sup></td></tr>
<tr>
<td align="justify">Peterson LR<sup><xref ref-type="bibr" rid="bibr29-1741826710396625">29</xref></sup></td>
<td align="justify">256</td>
<td align="justify">171 (67)</td>
<td align="justify">NA</td>
<td align="justify">16.3 ± 4.8</td>
<td align="justify">1.1 ± 0.1</td>
<td align="justify">NA</td>
<td align="justify">NA</td>
<td align="justify">Pts with peak VO2 &lt;12 ml/kg/min showed a 72–97% and 60–92% 1- and 3-year survival, respectively</td></tr>
<tr>
<td align="justify">Pohwani AL<sup><xref ref-type="bibr" rid="bibr30-1741826710396625">30</xref></sup></td>
<td align="justify">48</td>
<td align="justify">35 (73)</td>
<td align="justify">NA</td>
<td align="justify">12.7 ± 1.5</td>
<td align="justify">1.13 ± 0.19</td>
<td align="justify">3.5</td>
<td align="justify">71<sup><xref ref-type="table-fn" rid="table-fn3-1741826710396625">b</xref></sup></td>
<td align="justify">Mean 1- and 3-year survival was 92% and 71%, respectively </td></tr>
<tr>
<td align="justify">Lund LH<sup><xref ref-type="bibr" rid="bibr33-1741826710396625">33</xref></sup></td>
<td align="justify">144</td>
<td align="justify">120 (84)</td>
<td align="justify">NA</td>
<td align="justify">13 ± 3.7</td>
<td align="justify">NA</td>
<td align="justify">1.4</td>
<td align="justify">71<sup><xref ref-type="table-fn" rid="table-fn4-1741826710396625">c</xref></sup></td>
<td align="justify">Pts with peak VO2 ≤10 ml/kg/min and those with peak VO2 between 10 and 14 ml/kg/min showed a 72% and 74% mean survival, respectively</td></tr>
<tr>
<td align="justify">Shakar SF<sup><xref ref-type="bibr" rid="bibr34-1741826710396625">34</xref></sup></td>
<td align="justify">127</td>
<td align="justify">93 (73)</td>
<td align="justify">NA</td>
<td align="justify">18.1 ± 4.3</td>
<td align="justify">&gt;1.00 in 81% of pts</td>
<td align="justify">1</td>
<td align="justify">81</td>
<td align="justify">Pts with peak VO2 ≤14 ml/kg/min showed a 94% mean survival either at 12 and 30 months</td></tr>
<tr>
<td align="justify">Corrà U<sup><xref ref-type="bibr" rid="bibr35-1741826710396625">35</xref></sup></td>
<td align="justify">236</td>
<td align="justify">202 (86)</td>
<td align="justify">212 (89)</td>
<td align="justify">14.4 ± 3</td>
<td align="justify">1.18 ± 0.1</td>
<td align="justify">2.3</td>
<td align="justify">89</td>
<td align="justify">Survival rates according to peak VO2 ≤10 ml/kg/min, &gt;10 to ≤14 ml/kg/min, &gt;14–18 ml/kg/min, and ≥18 ml/kg/min were 74%, 89%, 90% and 96%, respectively</td></tr>
<tr>
<td align="justify">O’Neill JO<sup><xref ref-type="bibr" rid="bibr31-1741826710396625">31</xref></sup></td>
<td align="justify">909</td>
<td align="justify">680 (75)</td>
<td align="justify">909 (100)</td>
<td align="justify">16.6 ± 5.1</td>
<td align="justify">1.13</td>
<td align="justify">3.5</td>
<td align="justify">68</td>
<td align="justify">In a range of peak VO2 from 10 to 25 ml/kg/min, beta-blocker usage was associated with improved survival except when peak VO2 was 10 ml/kg/min or less</td></tr>
<tr>
<td align="justify">Tabet JY<sup><xref ref-type="bibr" rid="bibr36-1741826710396625">36</xref></sup></td>
<td align="justify">225</td>
<td align="justify">230 (89)</td>
<td align="justify">NA</td>
<td align="justify">15.4 ± 5.1</td>
<td align="justify">&gt;1.00 in all</td>
<td align="justify">2.1</td>
<td align="justify">82.4</td>
<td/></tr>
<tr>
<td align="justify">Arena RA<sup><xref ref-type="bibr" rid="bibr37-1741826710396625">37</xref></sup></td>
<td align="justify">167</td>
<td align="justify">139 (83)</td>
<td align="justify">NA</td>
<td align="justify">16.5 ± 5.5</td>
<td align="justify">1.05 ± 0.14</td>
<td align="justify">2</td>
<td align="justify">83</td>
<td align="justify">One-year survival was 92.8%</td></tr>
<tr>
<td align="justify">Corrà U<sup><xref ref-type="bibr" rid="bibr38-1741826710396625">38</xref></sup></td>
<td align="justify">631</td>
<td align="justify">565 (90)</td>
<td align="justify">583 (93)</td>
<td align="justify">15.5 ± 4</td>
<td align="justify">1.15 ± 0.1</td>
<td align="justify">3.4</td>
<td align="justify">87</td>
<td align="justify">Actuarial 2 and 4 year survival rates were 94% and 88%, respectively</td></tr>
<tr>
<td align="justify">Guimaraes GV<sup><xref ref-type="bibr" rid="bibr32-1741826710396625">32</xref></sup></td>
<td align="justify">229</td>
<td align="justify">174 (76)</td>
<td align="justify">NA</td>
<td align="justify">16.3 ± 5</td>
<td align="justify">&gt;1.00 in all</td>
<td align="justify">2.5</td>
<td align="justify">86</td>
<td align="justify">Event-free survival for patients with peak VO2 ≤12.5 and &gt;12.5 ml/kg/min was 72% and 97%, respectively</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1741826710396625"><p>Pts, patients; VO2, oxygen consumption; RER, gas exchange ratio; NA, not available.</p></fn>
<fn id="table-fn2-1741826710396625"><label>a</label><p>Data derived from figures not cited in the text.</p></fn>
<fn id="table-fn3-1741826710396625"><label>b</label><p>Mean survival, experiencing one combined end-point, death, heart transplantation (UNOS status I or II) or ventricular assist device placement.</p></fn>
<fn id="table-fn4-1741826710396625"><label>c</label><p>Outcome events: death, heart transplantation (UNOS status I) or ventricular assist device implantation.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>In a contradictory tendency, Lund et al.<sup><xref ref-type="bibr" rid="bibr33-1741826710396625">33</xref></sup> showed that peak VO2 categorization (≤10, 10.1–14 and &gt;14 ml/kg/min) at 1-year follow-up does not retain its predictive performance when beta-blockers were prescribed, while Shakar et al.<sup><xref ref-type="bibr" rid="bibr34-1741826710396625">34</xref></sup> documented that a peak VO2 cutoff of 14 ml/kg/min might not be associated with a poor enough prognosis to warrant listing for HT. Finally we demonstrated that HF patients taking carvedilol<sup><xref ref-type="bibr" rid="bibr35-1741826710396625">35</xref></sup> with peak VO2 ≤10 ml/kg/min had a ‘significantly’ higher total mortality rate than patients with a peak VO2 &gt;10 ml/kg/min, but the narrow difference in survival, approximately 10%, suggests that this dichotomizing prognostic stratification approach tends to oversimplify its clinical and outcome significance.</p>
</sec>
<sec id="sec7-1741826710396625"><title>Prognostic significance of CPET parameters beyond peak VO2</title>
<p>Few studies focused on various different CPET parameters in lieu of or in combination with peak VO2 in estimating risk in beta-blockers in HF patients.<sup><xref ref-type="bibr" rid="bibr31-1741826710396625">31</xref>,<xref ref-type="bibr" rid="bibr35-1741826710396625">35</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr38-1741826710396625">38</xref></sup> No supplementary CPET parameter was informative either in 236 carvedilol patients<sup><xref ref-type="bibr" rid="bibr35-1741826710396625">35</xref></sup> or in 909 treated with different types of beta-blockers.<sup><xref ref-type="bibr" rid="bibr31-1741826710396625">31</xref></sup> Conversely, Tabet at al.<sup><xref ref-type="bibr" rid="bibr36-1741826710396625">36</xref></sup> documented that peak circulatory power (CP = the product of peak VO2 by systolic blood pressure, an index reflecting the cardiac power response) was the best prognostic index of mortality, both in patients receiving (<italic>n</italic> = 255) and not receiving beta-blockers (<italic>n</italic> = 147). In patients on beta-blockers, the peak CP model had the highest predictive performance, superior to VE/VCO2, and peak VO2. Arena et al.<sup><xref ref-type="bibr" rid="bibr37-1741826710396625">37</xref></sup> screened HF patients – 167 taking beta-blockers and 250 not on beta-blockers – equally at 1-year and during overall follow-up, VE/VCO2 slope was the strongest CPET prognostic marker for cardiac-related events, HT, and implantation of left ventricular assistance device (LVAD), in both subgroups. In 2009, we evaluated 631 cardvedilol HF patients,<sup><xref ref-type="bibr" rid="bibr38-1741826710396625">38</xref></sup> followed for cardiovascular death over 3.8 ± 1.4 years: 79 (13%) patients died. Twelve CPET parameters were examined: percentage of predicted peak VO2, ventilatory anaerobic threshold (VAT), VO2 at VAT, peak oxygen pulse, peak CP, VE/VCO2 slope, peak VE/VCO2, the oxygen uptake efficiency slope, EOV, peak systolic blood pressure (SBP) and peak heart rate. Among CPET parameters, only peak SPB and EOV were selected as independent predictors, and peak SBP was the strongest risk index both in total and non-EOV populations, with 11% risk reduction for every 5 mmHg increase.</p>
</sec>
</sec>
<sec id="sec8-1741826710396625"><title>Algorithm proposal for heart failure patients treated with beta-blockers</title>
<p>In total, 12 ‘CPET and beta-blocker vs outcome’ studies (<xref ref-type="table" rid="table1-1741826710396625">Table 1</xref>) have been published to date, from which three messages can be derived.</p>
<p>First, an accurate assessment of maximal aerobic capacity is imperative for prognostic purposes. A high peak RER is needed to avoid inappropriate prognostic stratification.<sup><xref ref-type="bibr" rid="bibr39-1741826710396625">39</xref></sup> In all ‘CPET and β-blocker vs outcome’ studies except one,<sup><xref ref-type="bibr" rid="bibr37-1741826710396625">37</xref></sup> tests were conducted to a high peak RER. If peak RER is lower than 1, CPET interpretation for risk assessment could be distorted: Inge et al.<sup><xref ref-type="bibr" rid="bibr40-1741826710396625">40</xref></sup> showed that VE/VCO2 slope and peak VO2 were not predictive of mortality in elderly HF patients with a peak RER&lt;1.0. Unfortunately, these results were not adjusted for beta-blocker therapy.</p>
<p>Second, beta-blocker status does not change the predictive power of peak VO2 in most studies.<sup><xref ref-type="bibr" rid="bibr27-1741826710396625">27</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr31-1741826710396625">31</xref></sup> Importantly, mean survival in HF patients on beta-blockers is fairly good across a wide range of peak VO2<sup><xref ref-type="bibr" rid="bibr29-1741826710396625">29</xref>,<xref ref-type="bibr" rid="bibr31-1741826710396625">31</xref></sup> and, as a general rule, outcome for a patient with a peak VO2 of 12 ml/min/kg on beta-blockers may be no worse than that for another patient not on beta-blockers with a peak VO2 of 14 ml/min/kg.<sup><xref ref-type="bibr" rid="bibr27-1741826710396625">27</xref>,<xref ref-type="bibr" rid="bibr29-1741826710396625">29</xref>,<xref ref-type="bibr" rid="bibr31-1741826710396625">31</xref></sup></p>
<p>Third, most ‘CPET and beta-blocker vs outcome’ studies have documented that VE/VCO2 slope<sup><xref ref-type="bibr" rid="bibr35-1741826710396625">35</xref>,<xref ref-type="bibr" rid="bibr36-1741826710396625">36</xref>,<xref ref-type="bibr" rid="bibr38-1741826710396625">38</xref></sup> or as peak VE/VCO2<sup><xref ref-type="bibr" rid="bibr31-1741826710396625">31</xref></sup> do not provide predictive information, while EOV<sup><xref ref-type="bibr" rid="bibr38-1741826710396625">38</xref></sup> and, hemodynamic-derived CPET variables, either peak CP or peak SBP, add significant prognostic information in beta-blocker HF patients.<sup><xref ref-type="bibr" rid="bibr36-1741826710396625">36</xref>,<xref ref-type="bibr" rid="bibr38-1741826710396625">38</xref></sup></p>
<p>These statements can be synthesized in a new pilot prognosticating algorithm for stable HF patients treated with beta-blockers (<xref ref-type="fig" rid="fig1-1741826710396625">Figure 1</xref>). The algorithm entails four key CPET parameters, peak RER, EOV, peak VO2 and peak SBP, and it allows an incremental multi-parametric risk stratification, with four risk levels. In detail, the algorithm interpretation is as follows:
<fig id="fig1-1741826710396625" position="float"><label>Figure 1.</label><caption><p>Algorithm for risk stratification with symptom-limited cardiopulmonary exercise testing in HF patients on beta-blocker therapy. RER, peak respiratory exchange ratio; EOV, exertional oscillatory ventilation; VO2, peak oxygen consumption; SBP, peak systolic blood pressure.</p></caption><graphic xlink:href="10.1177_1741826710396625-fig1.tif"/></fig></p>
<p>1<sup>st</sup> step: peak RER. If peak RER is &lt;1.00, risk assessment with traditional CPET risk indexes might be inaccurate. We suggest repeating the test when clinical and functional conditions are optimized. If peak RER is ≥1.00, proceed to the next step.</p>
<p>2<sup>nd</sup> step: see EOV criteria. EOV defines a high risk HF patient. If EOV is not present, proceed to the next step.</p>
<p>3<sup>rd</sup> step: see peak VO2. A peak VO2 ≤12 ml/kg/min identifies an HF patient with moderate risk. If peak VO2 is &gt;12 ml/kg/min, proceed to the next step.</p>
<p>4<sup>th</sup> step: see peak SBP. In patients with peak VO2 &gt;12 ml/kg/min, peak SBP is introduced as a continuous risk variable, exploring a risk domain from low to mild, with 11% risk reduction for every 5 mmHg increase.</p>
</sec>
<sec id="sec9-1741826710396625" sec-type="discussion"><title>Discussion</title>
<p>Outcome assessment with CPET in HF patients treated with beta-blockers is a relatively modern area of research and, hence, the proposed CPET algorithm should be considered as a preliminary attempt. In addition, it is inherent with algorithm construction that continuous CPET parameters are forced into a ‘high/low risk’ categorization, which tends to oversimplify their predictive connotation.</p>
<p>As regards step 2, EOV patients tend to be poorly represented in a beta-blocker HF cohort,<sup><xref ref-type="bibr" rid="bibr38-1741826710396625">38</xref></sup> and further data are needed to describe the clinical impact of EOV in beta-blocker HF patients. The exclusion of VE/VCO2 slope is not easy to comprehend but few of the available studies demonstrated that VE/VCO2 prognostic strength is less obvious. While we wait for confirmation of this negative remark concerning the VE/VCO2 slope, this algorithm must be judged a preliminary attempt.</p>
<p>Finally, most ‘CPET and beta-blocker vs outcome’ studies have been conducted in sinus rhythm male HF patients: although female and atrial fibrillation (AF) patients showed a lower peak VO2 after adjusting for age, sex (for AF patients), left ventricular ejection fraction and cardiovascular therapy,<sup><xref ref-type="bibr" rid="bibr41-1741826710396625">41</xref>,<xref ref-type="bibr" rid="bibr42-1741826710396625">42</xref></sup> sex- and rhythm-based differences in the predictive CPET parameters have not been investigated in the beta-blocker era. Thus, new studies are necessary to avoid the scientific burden of considering HF patient characteristics in addition to CPET parameters for outcome definition.</p>
</sec>
<sec id="sec10-1741826710396625" sec-type="conclusions"><title>Conclusions</title>
<p>This review is based on a comprehensive examination of outcome CPET studies in HF patients treated with beta-blockers, and proposes a new pilot prognosticating algorithm that rests on four CPET parameters. This algorithm highlights the importance of a multi-parametric interpretation for risk assessment, and may assist clinicians in their decision-making. We believe that further studies are required to verify the predictive performance of this algorithm.</p>
</sec>
</body>
<back>
<sec id="sec11-1741826710396625"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</sec>
<sec id="sec12-1741826710396625"><title>Conflict of interest</title>
<p>The authors declare no conflict of interest.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-1741826710396625"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dickstein</surname><given-names>K</given-names></name><name><surname>Cohen-Solal</surname><given-names>A</given-names></name><name><surname>Filippatos</surname><given-names>G</given-names></name><name><surname>McMurray</surname><given-names>JJ</given-names></name><name><surname>Ponikowski</surname><given-names>P</given-names></name><name><surname>Poole-Wilson</surname><given-names>PA</given-names></name><etal/></person-group>. <article-title>ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)</article-title>. <source>Eur Heart J</source> <year>2008</year>; <volume>29</volume>: <fpage>2388</fpage>–<lpage>2442</lpage>.</citation></ref>
<ref id="bibr2-1741826710396625"><label>2</label><citation citation-type="journal"><collab>Heart Failure Society of America</collab>. <article-title>Executive summary: HFSA 2006 comprehensive heart failure practice guideline</article-title>. <source>J Card Fail</source> <year>2006</year>; <volume>12</volume>: <fpage>10</fpage>–<lpage>38</lpage>.</citation></ref>
<ref id="bibr3-1741826710396625"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Piepoli</surname><given-names>MF</given-names></name><name><surname>Corrà</surname><given-names>U</given-names></name><name><surname>Agostoni</surname><given-names>PG</given-names></name><name><surname>Belardinelli</surname><given-names>R</given-names></name><name><surname>Cohen-Solal</surname><given-names>A</given-names></name><name><surname>Hambrecht</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Task Force of the Italian Working Group on Cardiac Rehabilitation and Prevention (Gruppo Italiano di Cardiologia Riabilitativa e Prevenzione, GICR); Working Group on Cardiac Rehabilitation and Exercise Physiology of the European Society of Cardiology; tatement on cardiopulmonary exercise testing in chronic heart failure due to left ventricular dysfunction: recommendations for performance and interpretation, part III: interpretation of cardiopulmonary exercise testing in chronic heart failure and future applications</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2006</year>; <volume>13</volume>: <fpage>485</fpage>–<lpage>494</lpage>.</citation></ref>
<ref id="bibr4-1741826710396625"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Corra</surname><given-names>U</given-names></name><name><surname>Mezzani</surname><given-names>A</given-names></name><name><surname>Bosimini</surname><given-names>E</given-names></name><name><surname>Giannuzzi</surname><given-names>P</given-names></name></person-group>. <article-title>Cardiopulmonary exercise testing and prognosis in chronic heart failure: a prognosticating algorithm for the individual patient</article-title>. <source>Chest</source> <year>2004</year>; <volume>126</volume>: <fpage>942</fpage>–<lpage>950</lpage>.</citation></ref>
<ref id="bibr5-1741826710396625"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abdulla</surname><given-names>J</given-names></name><name><surname>Kober</surname><given-names>L</given-names></name><name><surname>Christensen</surname><given-names>E</given-names></name><name><surname>Torp-Pedersen</surname><given-names>C</given-names></name></person-group>. <article-title>Effect of beta-blocker therapy on functional status in patients with heart failure</article-title>. <source><italic>A meta-analysis</italic>. Eur J Heart Fail</source> <year>2006</year>; <volume>8</volume>: <fpage>522</fpage>–<lpage>531</lpage>.</citation></ref>
<ref id="bibr6-1741826710396625"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Metra</surname><given-names>M</given-names></name><name><surname>Giubbini</surname><given-names>R</given-names></name><name><surname>Nodari</surname><given-names>S</given-names></name><name><surname>Boldi</surname><given-names>E</given-names></name><name><surname>Modena</surname><given-names>MG</given-names></name><name><surname>Dei Cas</surname><given-names>L</given-names></name></person-group>. <article-title>Differential effects of B-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol</article-title>. <source>Circulation</source> <year>2000</year>; <volume>102</volume>: <fpage>546</fpage>–<lpage>551</lpage>.</citation></ref>
<ref id="bibr7-1741826710396625"><label>7</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Wolfel</surname><given-names>EE</given-names></name><name><surname>Bristow</surname><given-names>MR</given-names></name></person-group>. <article-title>Effects of long-term beta-adrenergic blockade on exercise capacity in patients with chronic heart failure</article-title>. In: <person-group person-group-type="editor"><name><surname>Balady</surname><given-names>GJ</given-names></name><name><surname>Pina</surname><given-names>IL</given-names></name></person-group> (eds) <source>Exercise and heart failure</source>. <publisher-loc>Armonk. NY</publisher-loc>: <publisher-name>Futura Publishing Co</publisher-name>, <year>1997</year>, pp. <fpage>141</fpage>–<lpage>170</lpage>.</citation></ref>
<ref id="bibr8-1741826710396625"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wolfel</surname><given-names>EE</given-names></name></person-group>. <article-title>Exercise testing with concurrent beta-blocker usage: is it useful? What do we learn?</article-title>. <source>Curr Heart Fail Rep</source> <year>2006</year>; <volume>3</volume>: <fpage>81</fpage>–<lpage>88</lpage>.</citation></ref>
<ref id="bibr9-1741826710396625"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wasserman</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Gitt</surname><given-names>A</given-names></name><name><surname>Belardinelli</surname><given-names>R</given-names></name><name><surname>Koike</surname><given-names>A</given-names></name><name><surname>Lubarsky</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Lung function and exercise gas exchange in chronic heart failure</article-title>. <source>Circulation</source> <year>1997</year>; <volume>96</volume>: <fpage>2221</fpage>–<lpage>2227</lpage>.</citation></ref>
<ref id="bibr10-1741826710396625"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Agostoni</surname><given-names>P</given-names></name><name><surname>Pellegrino</surname><given-names>R</given-names></name><name><surname>Conca</surname><given-names>C</given-names></name><name><surname>Rodarte</surname><given-names>JR</given-names></name><name><surname>Brusasco</surname><given-names>V</given-names></name></person-group>. <article-title>Exercise hyperpnea in chronic heart failure: relationships to lung stiffness and expiratory flow limitation</article-title>. <source>J Appl Physiol</source> <year>2002</year>; <volume>92</volume>: <fpage>1409</fpage>–<lpage>1416</lpage>.</citation></ref>
<ref id="bibr11-1741826710396625"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Agostoni</surname><given-names>P</given-names></name><name><surname>Palermo</surname><given-names>P</given-names></name><name><surname>Contini</surname><given-names>M</given-names></name></person-group>. <article-title>Respiratory effects of β-blocker therapy in heart failure</article-title>. <source>Cardiovasc Drugs Ther</source> <year>2009</year>; <volume>23</volume>: <fpage>377</fpage>–<lpage>84</lpage>.</citation></ref>
<ref id="bibr12-1741826710396625"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ponikowski</surname><given-names>P</given-names></name><name><surname>Chua</surname><given-names>TP</given-names></name><name><surname>Anker</surname><given-names>SD</given-names></name><name><surname>Francis</surname><given-names>DP</given-names></name><name><surname>Doehner</surname><given-names>W</given-names></name><name><surname>Banasiak</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Peripheral chemoreceptor hypersensitivity: an ominous sign in patients with chronic heart failure</article-title>. <source>Circulation</source> <year>2001</year>; <volume>104</volume>: <fpage>544</fpage>–<lpage>549</lpage>.</citation></ref>
<ref id="bibr13-1741826710396625"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tabet</surname><given-names>JY</given-names></name><name><surname>Beauvais</surname><given-names>F</given-names></name><name><surname>Thabut</surname><given-names>G</given-names></name><name><surname>Tartiere</surname><given-names>JM</given-names></name><name><surname>Logeart</surname><given-names>D</given-names></name><name><surname>Cohen-Solal</surname><given-names>A</given-names></name></person-group>. <article-title>A critical appraisal of the prognostic value of the VE/VCO2 slope in chronic heart failure patients</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2003</year>; <volume>10</volume>: <fpage>267</fpage>–<lpage>272</lpage>.</citation></ref>
<ref id="bibr14-1741826710396625"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Agostoni</surname><given-names>P</given-names></name><name><surname>Guazzi</surname><given-names>M</given-names></name><name><surname>Bussotti</surname><given-names>M</given-names></name><name><surname>De Vita</surname><given-names>S</given-names></name><name><surname>Palermo</surname><given-names>P</given-names></name></person-group>. <article-title>Carvedilol reduces the inappropriate increase of ventilation during exercise in heart failure patients</article-title>. <source>Chest</source> <year>2002</year>; <volume>122</volume>: <fpage>2062</fpage>–<lpage>2067</lpage>.</citation></ref>
<ref id="bibr15-1741826710396625"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Agostoni</surname><given-names>P</given-names></name><name><surname>Contini</surname><given-names>M</given-names></name><name><surname>Cattadori</surname><given-names>G</given-names></name><name><surname>Apostolo</surname><given-names>A</given-names></name><name><surname>Sciomer</surname><given-names>S</given-names></name><name><surname>Bussotti</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Lung function with carvedilol and bisoprolol in chronic heart failure: is beta selectivity relevant?</article-title>. <source>Eur J Heart Fail</source> <year>2007</year>; <volume>9</volume>: <fpage>827</fpage>–<lpage>833</lpage>.</citation></ref>
<ref id="bibr16-1741826710396625"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wolk</surname><given-names>R</given-names></name><name><surname>Johnson</surname><given-names>BD</given-names></name><name><surname>Somers</surname><given-names>VK</given-names></name><name><surname>Allison</surname><given-names>TG</given-names></name><name><surname>Squires</surname><given-names>RW</given-names></name><name><surname>Gau</surname><given-names>GT</given-names></name><etal/></person-group>. <article-title>Effects of beta-blocker therapy on ventilatory responses to exercise in patients with heart failure</article-title>. <source>J Card Fail</source> <year>2005</year>; <volume>11</volume>: <fpage>333</fpage>–<lpage>339</lpage>.</citation></ref>
<ref id="bibr17-1741826710396625"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Witte</surname><given-names>KK</given-names></name><name><surname>Thackray</surname><given-names>S</given-names></name><name><surname>Nikitin</surname><given-names>NP</given-names></name><name><surname>Cleland</surname><given-names>JG</given-names></name><name><surname>Clark</surname><given-names>AL</given-names></name></person-group>. <article-title>The effects of long-term beta-blockade on the ventilatory responses to exercise in chronic heart failure</article-title>. <source>Eur J Heart Fail</source> <year>2005</year>; <volume>7</volume>: <fpage>612</fpage>–<lpage>617</lpage>.</citation></ref>
<ref id="bibr18-1741826710396625"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kataoka</surname><given-names>M</given-names></name><name><surname>Satoh</surname><given-names>T</given-names></name><name><surname>Yoshikawa</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>I</given-names></name><name><surname>Kohno</surname><given-names>T</given-names></name><name><surname>Yoshizawa</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Comparison of the effects of carvedilol and metoprolol on exercise ventilatory efficiency in patients with congestive heart failure</article-title>. <source>Circ J</source> <year>2008</year>; <volume>72</volume>: <fpage>358</fpage>–<lpage>363</lpage>.</citation></ref>
<ref id="bibr19-1741826710396625"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ingle</surname><given-names>L</given-names></name><name><surname>Isted</surname><given-names>A</given-names></name><name><surname>Witte</surname><given-names>KK</given-names></name><name><surname>Cleland</surname><given-names>JGJF</given-names></name><name><surname>Clark</surname><given-names>AL</given-names></name></person-group>. <article-title>Impact of different diagnostic criteria on the prevalence and prognostic significance of exertional oscillatory ventilation in patients with chronic heart failure</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2009</year>; <volume>16</volume>: <fpage>451</fpage>–<lpage>456</lpage>.</citation></ref>
<ref id="bibr20-1741826710396625"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Corrà</surname><given-names>U</given-names></name><name><surname>Giordano</surname><given-names>A</given-names></name><name><surname>Bosimini</surname><given-names>E</given-names></name><name><surname>Mezzani</surname><given-names>A</given-names></name><name><surname>Piepoli</surname><given-names>M</given-names></name><name><surname>Coats</surname><given-names>AJS</given-names></name><etal/></person-group>. <article-title>Oscillatory ventilation during exercise in patients with chronic heart failure. Clinical correlates and prognostic implications</article-title>. <source>Chest</source> <year>2002</year>; <volume>121</volume>: <fpage>1572</fpage>–<lpage>1580</lpage>.</citation></ref>
<ref id="bibr21-1741826710396625"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leite</surname><given-names>JJ</given-names></name><name><surname>Mansur</surname><given-names>AJ</given-names></name><name><surname>de Freitas</surname><given-names>HF</given-names></name><name><surname>Chizola</surname><given-names>PR</given-names></name><name><surname>Bocchi</surname><given-names>EA</given-names></name><name><surname>Terra-Filho</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Periodic breathing during incremental exercise predicts mortality in patients with chronic heart failure evaluated for cardiac transplantation</article-title>. <source>J Am Coll Cardiol</source> <year>2003</year>; <volume>41</volume>: <fpage>2175</fpage>–<lpage>2181</lpage>.</citation></ref>
<ref id="bibr22-1741826710396625"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guazzi</surname><given-names>M</given-names></name><name><surname>Arena</surname><given-names>R</given-names></name><name><surname>Ascione</surname><given-names>A</given-names></name><name><surname>Piepoli</surname><given-names>M</given-names></name><name><surname>Guazzi</surname><given-names>MD</given-names></name></person-group>. <article-title>Exercise oscillatory breathing and increased ventilation to carbon dioxide production slope in heart failure: An unfavorable combination with high prognostic value</article-title>. <source>Am Heart J</source> <year>2007</year>; <volume>153</volume>: <fpage>859</fpage>–<lpage>867</lpage>.</citation></ref>
<ref id="bibr23-1741826710396625"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guazzi</surname><given-names>M</given-names></name><name><surname>Raimondo</surname><given-names>R</given-names></name><name><surname>Vicenzi</surname><given-names>M</given-names></name><name><surname>Arena</surname><given-names>R</given-names></name><name><surname>Proserpio</surname><given-names>C</given-names></name><name><surname>Sarzi Braga</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Exercise oscillatory ventilation may predict sudden cardiac death in heart failure patients</article-title>. <source>J Am Coll Cardiol</source> <year>2007</year>; <volume>50</volume>: <fpage>299</fpage>–<lpage>308</lpage>.</citation></ref>
<ref id="bibr24-1741826710396625"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Piepoli</surname><given-names>MF</given-names></name><name><surname>Ponikowski</surname><given-names>PP</given-names></name><name><surname>Volterrani</surname><given-names>M</given-names></name><name><surname>Francis</surname><given-names>D</given-names></name><name><surname>Coats</surname><given-names>AJ</given-names></name></person-group>. <article-title>Aetiology and pathophysiological implications of oscillatory ventilation at rest and during exercise in CHF: do Cheyne and Stokes have an important message for modern-day patients with heart failure?</article-title>. <source>Eur Heart J</source> <year>1999</year>; <volume>20</volume>: <fpage>946</fpage>–<lpage>953</lpage>.</citation></ref>
<ref id="bibr25-1741826710396625"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>R</given-names></name></person-group>. <article-title>Gas exchange efficiency in congestive heart failure</article-title>. <source>Circulation</source> <year>2000</year>; <volume>101</volume>: <fpage>2774</fpage>–<lpage>2776</lpage>.</citation></ref>
<ref id="bibr26-1741826710396625"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ponikowski</surname><given-names>P</given-names></name><name><surname>Francis</surname><given-names>DP</given-names></name><name><surname>Piepoli</surname><given-names>MF</given-names></name><name><surname>Davies</surname><given-names>LC</given-names></name><name><surname>Chua</surname><given-names>TP</given-names></name><name><surname>Davos</surname><given-names>CH</given-names></name><etal/></person-group>. <article-title>Enhanced ventilatory response to exercise in patients with chronic heart failure and preserved exercise tolerance: marker of abnormal cardiorespiratory reflex control and predictor of poor prognosis</article-title>. <source>Circulation</source> <year>2001</year>; <volume>103</volume>: <fpage>967</fpage>–<lpage>972</lpage>.</citation></ref>
<ref id="bibr27-1741826710396625"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zugck</surname><given-names>C</given-names></name><name><surname>Haunstetter</surname><given-names>A</given-names></name><name><surname>Kruger</surname><given-names>C</given-names></name><name><surname>Kell</surname><given-names>R</given-names></name><name><surname>Schellberg</surname><given-names>D</given-names></name><name><surname>Kubler</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Impact of beta-blocker treatment on the prognostic value of currently used risk predictors in congestive heart failure</article-title>. <source>J Am Coll Cardiol</source> <year>2002</year>; <volume>39</volume>: <fpage>1615</fpage>–<lpage>1622</lpage>.</citation></ref>
<ref id="bibr28-1741826710396625"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peterson</surname><given-names>LR</given-names></name><name><surname>Schechtman</surname><given-names>KB</given-names></name><name><surname>Ewald</surname><given-names>GA</given-names></name><name><surname>Geltman</surname><given-names>EM</given-names></name><name><surname>Meyer</surname><given-names>T</given-names></name><name><surname>Krekeler</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>The effect of β-adrenergic blockers on the prognostic value of peak exercise oxygen uptake in patients with heart failure</article-title>. <source>J Heart Lung Transplant</source> <year>2003</year>; <volume>22</volume>: <fpage>70</fpage>–<lpage>77</lpage>.</citation></ref>
<ref id="bibr29-1741826710396625"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peterson</surname><given-names>LR</given-names></name><name><surname>Schechtman</surname><given-names>KB</given-names></name><name><surname>Ewald</surname><given-names>GA</given-names></name><name><surname>Geltman</surname><given-names>EM</given-names></name><name><surname>de las Fuentes</surname><given-names>L</given-names></name><name><surname>Meyer</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Timing of cardiac transplantation in patients with heart failure receiving beta-adrenergic blockers</article-title>. <source>J Heart Lung Transplant</source> <year>2003</year>; <volume>22</volume>: <fpage>1141</fpage>–<lpage>1148</lpage>.</citation></ref>
<ref id="bibr30-1741826710396625"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pohwani</surname><given-names>AL</given-names></name><name><surname>Murali</surname><given-names>S</given-names></name><name><surname>Matheir</surname><given-names>MM</given-names></name><name><surname>Tokarczyk</surname><given-names>T</given-names></name><name><surname>Kormos</surname><given-names>RL</given-names></name><name><surname>McNamara</surname><given-names>DM</given-names></name><etal/></person-group>. <article-title>Impact of β-blocker therapy on functional capacity criteria for heart tranplant listing</article-title>. <source>J Heart Lung Transplant</source> <year>2003</year>; <volume>22</volume>: <fpage>78</fpage>–<lpage>86</lpage>.</citation></ref>
<ref id="bibr31-1741826710396625"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O’Neill</surname><given-names>JO</given-names></name><name><surname>Young</surname><given-names>JB</given-names></name><name><surname>Pothier</surname><given-names>CE</given-names></name><name><surname>Lauer</surname><given-names>MS</given-names></name></person-group>. <article-title>Peak oxygen consumption as a predictor of death in patients with heart failure receiving beta-blockers</article-title>. <source>Circulation</source> <year>2005</year>; <volume>111</volume>: <fpage>2313</fpage>–<lpage>2318</lpage>.</citation></ref>
<ref id="bibr32-1741826710396625"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guimaraes</surname><given-names>GV</given-names></name><name><surname>d'Avila</surname><given-names>VM</given-names></name><name><surname>Silva</surname><given-names>MS</given-names></name><name><surname>Ferreira</surname><given-names>SA</given-names></name><name><surname>Ciolac</surname><given-names>EG</given-names></name><name><surname>Carvalho</surname><given-names>VO</given-names></name><etal/></person-group>. <article-title>A cutoff point for peak oxygen consumption in the prognosis of heart failure patients with beta-blocker therapy</article-title>. <source>Int J Cardiol</source> <year>2010</year>; <volume>145</volume>(<issue>1</issue>): <fpage>75</fpage>–<lpage>77</lpage>.</citation></ref>
<ref id="bibr33-1741826710396625"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lund</surname><given-names>LH</given-names></name><name><surname>Aaronson</surname><given-names>KD</given-names></name><name><surname>Mancini</surname><given-names>DM</given-names></name></person-group>. <article-title>Predicting survival in ambulatory patients with severe heart failure on beta-blocker therapy</article-title>. <source>Am J Cardiol</source> <year>2003</year>; <volume>92</volume>: <fpage>1350</fpage>–<lpage>1354</lpage>.</citation></ref>
<ref id="bibr34-1741826710396625"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shakar</surname><given-names>SF</given-names></name><name><surname>Lowes</surname><given-names>BD</given-names></name><name><surname>Lindenfeld</surname><given-names>J</given-names></name><name><surname>Zolty</surname><given-names>R</given-names></name><name><surname>Simon</surname><given-names>M</given-names></name><name><surname>Robertson</surname><given-names>AD</given-names></name><etal/></person-group>. <article-title>Peak oxygen consumption and outcome in heart failure patients chronically treated with beta-blockers</article-title>. <source>J Card Fail</source> <year>2004</year>; <volume>10</volume>: <fpage>15</fpage>–<lpage>20</lpage>.</citation></ref>
<ref id="bibr35-1741826710396625"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Corrà</surname><given-names>U</given-names></name><name><surname>Mezzani</surname><given-names>A</given-names></name><name><surname>Bosimini</surname><given-names>E</given-names></name><name><surname>Scapellato</surname><given-names>F</given-names></name><name><surname>Temporelli</surname><given-names>PL</given-names></name><name><surname>Eleuteri</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Limited predictive value of cardiopulmonary exercise indices in patients with moderate chronic heart failure treated with carvedilol</article-title>. <source>Am Heart J</source> <year>2004</year>; <volume>147</volume>: <fpage>553</fpage>–<lpage>560</lpage>.</citation></ref>
<ref id="bibr36-1741826710396625"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tabet</surname><given-names>JY</given-names></name><name><surname>Metra</surname><given-names>M</given-names></name><name><surname>Thabut</surname><given-names>G</given-names></name><name><surname>Logeart</surname><given-names>D</given-names></name><name><surname>Cohen-Solal</surname><given-names>A</given-names></name></person-group>. <article-title>Prognostic value of cardiopulmonary exercise variables in chronic heart failure patients with or without beta-blocker therapy</article-title>. <source>Am J Cardiol</source> <year>2006</year>; <volume>98</volume>: <fpage>500</fpage>–<lpage>503</lpage>.</citation></ref>
<ref id="bibr37-1741826710396625"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arena</surname><given-names>RA</given-names></name><name><surname>Guazzi</surname><given-names>M</given-names></name><name><surname>Myers</surname><given-names>J</given-names></name><name><surname>Abella</surname><given-names>J</given-names></name></person-group>. <article-title>The prognostic value of ventilatory efficacy with beta-blocker therapy in heart failure</article-title>. <source>Med Sci Sports Exerc</source> <year>2007</year>; <volume>39</volume>: <fpage>213</fpage>–<lpage>219</lpage>.</citation></ref>
<ref id="bibr38-1741826710396625"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Corrà</surname><given-names>U</given-names></name><name><surname>Mezzani</surname><given-names>A</given-names></name><name><surname>Giordano</surname><given-names>A</given-names></name><name><surname>Bosimini</surname><given-names>E</given-names></name><name><surname>Giannuzzi</surname><given-names>P</given-names></name></person-group>. <article-title>Exercise hemodynamic variables rather than ventilatory efficiency indexes contribute to risk assessment in chronic heart failure patients treated with carvedilol</article-title>. <source>Eur Heart J</source> <year>2009</year>; <volume>27</volume>: <fpage>684</fpage>–<lpage>690</lpage>.</citation></ref>
<ref id="bibr39-1741826710396625"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mezzani</surname><given-names>A</given-names></name><name><surname>Corrà</surname><given-names>U</given-names></name><name><surname>Giordano</surname><given-names>A</given-names></name><name><surname>Giannuzzi</surname><given-names>P</given-names></name></person-group>. <article-title>Contribution of peak respiratory exchange ratio to peak VO2 prognostic reliability in patients with chronic heart failure and severely reduced exercise capacity</article-title>. <source>Am Heart J</source> <year>2003</year>; <volume>145</volume>: <fpage>1102</fpage>–<lpage>1107</lpage>.</citation></ref>
<ref id="bibr40-1741826710396625"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ingle</surname><given-names>L</given-names></name><name><surname>Witte</surname><given-names>KK</given-names></name><name><surname>Cleland</surname><given-names>JGJF</given-names></name><name><surname>Clark</surname><given-names>AL</given-names></name></person-group>. <article-title>The prognostic value of cardiopulmonary exercise testing with a peak respiratory exchange ratio of &lt;1.0 in patients with chronic heart failure</article-title>. <source>Int J Cardiol</source> <year>2008</year>; <volume>127</volume>: <fpage>88</fpage>–<lpage>92</lpage>.</citation></ref>
<ref id="bibr41-1741826710396625"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Daida</surname><given-names>H</given-names></name><name><surname>Allison</surname><given-names>TG</given-names></name><name><surname>Johnson</surname><given-names>BD</given-names></name><name><surname>Squires</surname><given-names>RW</given-names></name><name><surname>Gau</surname><given-names>GT</given-names></name></person-group>. <article-title>Comparison of peak exercise uptake in men versus women in chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy</article-title>. <source>Am J Cardiol</source> <year>1997</year>; <volume>80</volume>: <fpage>85</fpage>–<lpage>88</lpage>.</citation></ref>
<ref id="bibr42-1741826710396625"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Agostoni</surname><given-names>PG</given-names></name><name><surname>Emdin</surname><given-names>M</given-names></name><name><surname>Corrà</surname><given-names>U</given-names></name><name><surname>Veglia</surname><given-names>F</given-names></name><name><surname>Magrì</surname><given-names>D</given-names></name><name><surname>Tedesco</surname><given-names>CC</given-names></name><etal/></person-group>. <article-title>Permanent atrial fibrillation affects exercise capacity in chronic heart failure patients</article-title>. <source>Eur Heart J</source> <year>2008</year>; <volume>29</volume>: <fpage>2367</fpage>–<lpage>2372</lpage>.</citation></ref>
</ref-list>
</back>
</article>